Perceptive Advisors - TRAVERE THERAPEUTICS INC ownership

TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of TRAVERE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,576,000
+156.5%
400,000
+340.8%
0.12%
+197.5%
Q2 2023$1,393,889
-31.7%
90,7480.0%0.04%
-33.3%
Q1 2023$2,040,923
+6.9%
90,7480.0%0.06%
+11.1%
Q4 2022$1,908,430
-14.6%
90,7480.0%0.05%
-16.9%
Q3 2022$2,236,000
-83.8%
90,748
-84.1%
0.06%
-85.0%
Q2 2022$13,813,000
-71.0%
570,084
-69.1%
0.43%
-54.6%
Q1 2022$47,560,000
-58.5%
1,845,555
-50.0%
0.95%
+7.8%
Q4 2021$114,572,000
+140.4%
3,691,110
+87.8%
0.88%
+27.7%
Q3 2021$47,665,000
-11.5%
1,965,555
-46.7%
0.69%
+97.7%
Q2 2021$53,854,000
-34.6%
3,691,110
+11.9%
0.35%
-66.4%
Q1 2021$82,362,000
-13.5%
3,298,419
-5.6%
1.04%
+2.0%
Q4 2020$95,218,0003,493,6071.02%
Other shareholders
TRAVERE THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Finepoint Capital LP 895,821$8,008,6403.99%
Deep Track Capital, LP 7,370,000$65,887,8002.54%
VR Adviser, LLC 2,623,677$23,455,6722.47%
Sio Capital Management, LLC 884,770$7,909,8442.45%
Kynam Capital Management, LP 957,502$8,560,0681.40%
MPM BioImpact LLC 552,846$4,942,4431.32%
ARMISTICE CAPITAL, LLC 7,500,000$67,050,0001.03%
Parkman Healthcare Partners LLC 577,494$5,162,7960.95%
Tri Locum Partners LP 251,702$2,250,2160.72%
Cheyne Capital Management (UK) LLP 26,200$234,2280.68%
View complete list of TRAVERE THERAPEUTICS INC shareholders